3 › 3.3 › 3.3.4
3.3.4 Classifications of treatments in HF
Pages 17–19 · open in PDF
Text below is machine-extracted from the PDF page(s) listed; two-column layouts and tables can read out of order, and neighbouring sections on the same page are included. Use the PDF link for the authoritative layout.
Page 17 · PDF
3.3.2. Classification based on heart failure stages An additional classification based on HF stages has been proposed previously.4 The Task Force has included this classification as we focus more on prevention of HF and early diagnosis (Figure 2).
3.3.3. Other classifications of heart failure
3.3.4. Classifications of treatments in heart failure The term guideline-directed medical therapy (GDMT) was introduced in the 2013 ACCF/AHA Guideline for the management of heart failure and is the cornerstone of pharmacological treatment for patients with HF.49 The term was meant to represent optimal medical therapy primarily with a Class I recommendation, which at that time included treatment with angiotensin-
Figure 2 Heart failure stages and classifications. AMT, additional medical therapy; FMT, foundational medical therapy; GDIT, guidelinedirected interventional therapy; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LVEF, left ventricular ejection fraction. aSee section 4.1. Not all will develop HF, but risk factor intervention may be warranted. bFor example, left ventricular hypertrophy, cardiac chamber enlargement, ventricular wall motion abnormality, myocardial tissue abnormality (e.g. evidence of myocardial oedema, scar/fibrosis abnormality by T2-weighted cardiac magnetic resonance imaging or late gadolinium enhancement imaging), valvular heart disease. cFor example, reduced left or right ventricular systolic function, evidence of increased filling pressures (by invasive or non-invasive measures), abnormal diastolic function. dEspecially in the setting of exposure to cardiotoxins. eFor details see Table 14.
Heart failure can also be classified according to clinical presentation: de novo (patients without a previous diagnosis of HF) vs pre-existing (patients with a diagnosis of HF), and chronic HF vs decompensated HF (DHF). Chronic HF may deteriorate to DHF. Details on the definitions and subtypes of DHF are provided in Section 7. Finally, an additional classification in isolated left-sided HF vs isolated right-sided HF vs combined left- and right-sided HF can be used. The main aetiology of chronic right-sided HF is LV dysfunction-induced pulmonary hypertension [World Health
Organization (WHO) group 2] leading to combined left- and right-sided HF. However, there are a number of causes of isolated right-sided HF, e.g. right ventricular (RV) myocardial infarction (MI); arrhythmogenic RV cardiomyopathy (ARVC); pulmonary hypertension WHO groups 1, 3, 4, and 5; and tricuspid or pulmonary valve regurgitation. Diagnosis and management of chronic right-sided HF is covered comprehensively in a recent Heart Failure Association (HFA) position paper.48
Page 18 · PDF
Foundational medical therapy (FMT) constitutes the foundation of any HF management. Foundational medical therapy is defined as medical therapy with a guideline Class I recommendation for the treatment of the general HF population, with convincing evidence of an improvement in morbidity and/or mortality. In this guideline, FMT will include beta-blocker, ACE-I/ARNI/ARB, MRA, and SGLT2-I for HFrEF, and MRA and SGLT2-I for HFpEF. The term ‘optimal FMT’ may be used for FMT at the highest tolerated doses according to the guideline-recommended target doses (see Section 6.1). Medical therapies with a Class I recommendation only for specific subsets of patients with HF are not included in the definition of FMT. Additional medical therapy (AMT) is defined as all other medical therapies that receive a Class IIa/IIb recommendation OR a Class I recommendation with proven effect only on symptoms and/or quality of life (QoL) OR a Class I recommendation in specific subsets of patients/HF phenotypes. Guideline-directed medical therapy therefore covers both FMT and AMT. Guideline-directed interventional therapy (GDIT) includes all cardiac implantable electronic devices (CIED) and interventional therapies that have a recommendation in the guidelines.
Figure 3 New nomenclature for heart failure therapies. Guideline-directed medical therapy (GDMT) includes foundational medical therapy (FMT) and additional medical therapy (AMT). Guideline directed interventional therapy is abbreviated as GDIT.
converting enzyme inhibitors (ACE-Is)/angiotensin II receptor blockers (ARBs), beta-blockers, and mineralocorticoid receptor antagonists (MRAs) for HFrEF. Since 2013, there have been further advances in the management of patients with HF. Class I recommendations have now been presented for the use of angiotensin receptor–neprilysin inhibitors (ARNIs) and sodium– glucose co-transporter 2 inhibitors (SGLT2-Is) in HFrEF. Furthermore, there are now data to support Class I recommendations for the use of SGLT2-Is and MRAs in HFpEF. Although these foundational therapies are crucial to improving the prognosis in HF, many other pharmacotherapies have guideline recommendations, e.g. ivabradine, vericiguat, cardiac glycosides, and, more recently, glucagon-like peptide-1 receptor agonists (GLP-1 RAs). All of these therapies could be viewed as GDMT but are currently not included in the definition of GDMT. Furthermore, the use of the term GDMT ignores the crucial role of devices that work in synergy with medical therapy and new procedural therapies with effect on patient-reported outcomes, morbidity and mortality. The current Task Force has decided to introduce new classifications to describe medical, device, and procedural therapies in HF (Figure 3). These classifications are designed to be dynamic, so the terms can remain contemporary over time as new therapies may be easily incorporated into the terms.
Page 19 · PDF
4. Prevention of heart failure 4.1. Patients at risk of heart failure (stage A heart failure) 4.1.1. Cardiometabolic risk factors
4.1.2. Risk scores for individuals without heart failure To assist in more individualized HF risk estimation, the use of risk scores may be considered. In addition to risk scores to predict HFH and mortality among ambulatory patients with established HF77–80 several risk scores for primary HF prevention have been developed81–83. The American Heart Association (AHA) PREVENT-HF risk score81 and the ESC SCORE2-HF82 were both derived to estimate risk in people without pre-existing HF over a 10-and 30-year horizon. The ESC risk scores have been calibrated for low-, moderate-, high-, and very high-risk countries to fit the European population. The ESC SMART2-HF risk score83 was derived to estimate 10-year risk of HF in people
4.1.3. Lifestyle-related factors 4.1.3.1. Diet and physical activity Epidemiological studies have shown that diets high in sugars, saturated fats, refined grains, and processed food are associated with increased HF risk (especially HFpEF).84–90 In contrast, adherence to a diet rich in vegetables, nuts, whole grains, fish, and unsaturated fats have been associated with lowered HF risk.84,87 However, a secondary analysis of the PREDIMED trial comparing a Mediterranean diet (with olive oil vs nuts) to a lowfat diet in individuals at high risk of CVD did not show a significant difference in HF incidence between the groups over a median follow-up of 4.8 years.89 Similarly, sedentary behaviour and physical inactivity are strong risk factors for especially HFpEF development60,91, but no randomized controlled trials (RCTs) have investigated the role of physical activity for the prevention of HF.91–93 Recommendations on exercise type and intensity to promote general CV health are outlined in the 2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease.94
4.1.3.2. Smoking, alcohol, and substance abuse Smoking cessation has been shown to reduce HF risk over time in epidemiological studies and should be encouraged in all individuals.95–97 Similarly, heavy alcohol use is associated with increased risk of HF and is discouraged, whereas light-to-moderate intake has shown more mixed data with regard to HF risk.98 Any form of substance abuse, recreational or continuous, with drugs such as cocaine, amphetamine, and anabolic steroids is associated with increased risk of cardiomyopathy and HF.99–101 If use is suspected, this should be addressed with the patient and advised against. Recommendation Table 1 — Recommendations for prevention of heart failure (see Evidence Tables 1–15) Recommendations
Strict blood pressure control (systolic blood pressure target <130 mmHg) is recommended in patients with hypertension or stage B HF to reduce the risk of HF.63–69,102 An SGLT2-I is recommended in patients with T2DM at risk of HF (multiple ASCVD risk factors or established ASCVD) to reduce the risk of HF and CV death.103 An SGLT2-I is recommended in patients with T2DM and CKDc to reduce the risk of HF or CV death.104 Finerenone is recommended in patients with T2DM and CKDd to reduce the risk of HF.105–108
Diabetes, hypertension, obesity, and smoking account for approximately 50% of all HF events on a population-based level, ranging from 30%–40% among the oldest individuals (over 75 years) to 75%–80% among individuals aged <55 years, and are similar for HFpEF and HFrEF.50–52 These risk factors often cluster within the same individuals and tend to be stable over the life course unless intervened upon.53–56 Unhealthy lifestyle changes have led to a rising incidence and prevalence of obesity, hypertension, and type 2 diabetes over the past decades in many regions across Europe, particularly among young to middle-aged adults.57–59 Concomitantly, increases have been observed in the incidence rates of HF among young adults, underscoring the need for earlier and better prevention strategies on a population-based level.16,19,20 As the risk of HF is related to both risk-factor burden (intensity) and risk-factor duration (exposure time), early risk-factor management should be considered for younger people with longer anticipated exposure time. Personalized HF risk estimations (see Section 4.1.2) may aid clinicians and patients in discussions, management, and treatment decisions. Specific recommendations on the management of obesity, hypertension, and diabetes are outlined in the ESC guidelines on prevention of CV disease (CVD), hypertension, and diabetes, respectively.60–62 For hypertension, most evidence supports targeting a blood pressure <130 mmHg to reduce HF risk, although there are likely additional benefits of achieving lower treatment targets if tolerated.63–69 For diabetes, glucose-lowering drugs without proven HF safety should be avoided,70 and among those at particular risk of HF [especially in the presence of atherosclerotic CVD (ASCVD)], SGLT2-Is and GLP-1 RAs have been shown to lower risk of HFH and CV death.71–73 For obesity, declines in fat mass and waist circumference, but not lean mass, lowers HF risk and should be targeted.74 High cholesterol levels increase the risk of HF mainly through CAD, and the use of statins has shown to modestly lower HF events in people at high risk of ASCVD and HF.75,76
with pre-existing ASCVD. These risk scores are described in Supplementary data online, Section S1 and Figure S1.